While infusion pumps are the most widely deployed connected medical devices, they are not the leading cause of security alerts.
Qualcomm Life announced an exclusive licensing agreement with AlertWatch, creator of an FDA-cleared intelligence care software that assists in the care of patients in the operating room. The deal will give Qualcomm Life the exclusive rights to sell AlertWatch, which the company plans to showcase at HIMSS 2018.
The mobile health industry is exploding, and it’s not just because more Americans than ever own smart devices. Providers and patients alike are realizing real value in mobile health technology as advancements ease the path to greater efficiency and lower costs.
The national average colorectal screening rate is 39 percent but at Albany Area Primary Health Care it's 60 percent.
It had been a few years since the last systematic literature review of the effect health information technology (HIT) has on patient outcomes, and much has changed since. The Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 encouraged widespread electronic health record (EHR) adoption, vaulting them to near-ubiquity.
A machine learning technology developed to spot dangerous medical conditions before they worsen has shown its value in a trial.
Sanofi has found yet another partner to help digitize its clinical trial processes. In a statement, TriNetX announced that it will be assisting the pharmaceutical company by using patient EHRs to optimize recruitment, streamline trial investigators’ workflows, and otherwise impact the design of investigational drug trials. Sanofi has made similar arrangements to bolster its clinical trials with Science 37 and Evidation in March and July of last year, respectively.
Chilmark Vice President Kenneth Kleinberg said that hospitals are deploying AI, image recognition, natural language processing, predictive analytics - and they’re doing so quickly.
Brett Swenson, MD, deployed a chatbot to improve engagement from EHRs to triage and found real success in reaching patients with information about flu shots.
Boehringer Ingelheim announced the approval of a new indication for afatinib (Gilotrif), as the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (NDA) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.